NGM Biopharmaceuticals (NYSE:NGM) Director Peter Svennilson purchased 148,464 shares of the company’s stock in a transaction that occurred on Thursday, March 19th. The stock was acquired at an average price of $11.59 per share, for a total transaction of $1,720,697.76. Following the purchase, the director now owns 20,000 shares in the company, valued at approximately $231,800. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Peter Svennilson also recently made the following trade(s):

  • On Thursday, March 5th, Peter Svennilson purchased 8,307 shares of NGM Biopharmaceuticals stock. The stock was acquired at an average price of $18.00 per share, for a total transaction of $149,526.00.
  • On Tuesday, March 3rd, Peter Svennilson purchased 38,758 shares of NGM Biopharmaceuticals stock. The stock was acquired at an average price of $17.99 per share, for a total transaction of $697,256.42.
  • On Thursday, February 27th, Peter Svennilson purchased 33,896 shares of NGM Biopharmaceuticals stock. The stock was acquired at an average price of $17.91 per share, for a total transaction of $607,077.36.

NGM stock opened at $13.33 on Thursday. The business’s fifty day moving average price is $15.71 and its two-hundred day moving average price is $15.69. NGM Biopharmaceuticals has a fifty-two week low of $8.81 and a fifty-two week high of $22.95.

NGM Biopharmaceuticals (NYSE:NGM) last posted its quarterly earnings data on Tuesday, March 17th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.02. The firm had revenue of $31.08 million for the quarter, compared to the consensus estimate of $5.00 million.

Several institutional investors and hedge funds have recently modified their holdings of the company. Svennilson Peter raised its position in shares of NGM Biopharmaceuticals by 1.6% during the fourth quarter. Svennilson Peter now owns 16,420,829 shares of the company’s stock worth $303,621,000 after acquiring an additional 253,922 shares during the last quarter. State Street Corp raised its position in shares of NGM Biopharmaceuticals by 190.2% during the fourth quarter. State Street Corp now owns 376,673 shares of the company’s stock worth $6,965,000 after acquiring an additional 246,853 shares during the last quarter. Candriam Luxembourg S.C.A. raised its position in shares of NGM Biopharmaceuticals by 56.1% during the fourth quarter. Candriam Luxembourg S.C.A. now owns 242,000 shares of the company’s stock worth $4,475,000 after acquiring an additional 87,000 shares during the last quarter. Nuveen Asset Management LLC raised its position in shares of NGM Biopharmaceuticals by 833.4% during the fourth quarter. Nuveen Asset Management LLC now owns 222,469 shares of the company’s stock worth $4,113,000 after acquiring an additional 198,635 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of NGM Biopharmaceuticals by 98.1% during the fourth quarter. Geode Capital Management LLC now owns 187,091 shares of the company’s stock worth $3,459,000 after acquiring an additional 92,660 shares during the last quarter.

NGM has been the topic of a number of research analyst reports. B. Riley restated a “buy” rating and issued a $30.00 price target on shares of NGM Biopharmaceuticals in a research note on Thursday, March 19th. Zacks Investment Research upgraded NGM Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research note on Thursday, March 19th. Cowen restated a “buy” rating and issued a $30.00 price target on shares of NGM Biopharmaceuticals in a research note on Monday. Citigroup increased their price target on NGM Biopharmaceuticals from $31.00 to $34.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th. Finally, Stifel Nicolaus dropped their price target on NGM Biopharmaceuticals from $33.00 to $32.00 and set a “buy” rating on the stock in a research note on Thursday, March 19th. Six investment analysts have rated the stock with a buy rating, NGM Biopharmaceuticals has a consensus rating of “Buy” and an average target price of $26.83.

NGM Biopharmaceuticals Company Profile

NGM Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity.

Further Reading: What is a Roth IRA?

Insider Buying and Selling by Quarter for NGM Biopharmaceuticals (NYSE:NGM)

Receive News & Ratings for NGM Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NGM Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.